Avalo Therapeutics (AVTX) Non-Current Debt (2014 - 2023)

Avalo Therapeutics' Non-Current Debt history runs 8 years deep, the most recent figure standing at $10.5 million for Q1 2023.

• Quarterly Non-Current Debt fell 68.45% year-over-year to $10.5 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $10.5 million (down 68.45% YoY) and the FY2022 annual result came in at $13.5 million, down 58.93% from the prior year.
• Non-Current Debt was $10.5 million for Q1 2023 at Avalo Therapeutics, down from $13.5 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $33.2 million in Q1 2022 and bottomed at $10.5 million in Q1 2023.
• A 4-year average of $19.8 million and a median of $16.5 million in 2022 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt rose 9.16% — and 2023, when it sank 68.45%.
• Avalo Therapeutics' Non-Current Debt stood at $14.3 million in 2019, then surged by 130.33% to $32.8 million in 2021, then tumbled by 58.93% to $13.5 million in 2022, then dropped by 22.36% to $10.5 million in 2023.
• Business Quant data shows AVTX's Non-Current Debt at $10.5 million in Q1 2023, $13.5 million in Q4 2022, and $16.5 million in Q3 2022.